Suspected Eczema Herpeticum
Atopic patient with acute vesicular eruption
All Pathways
DermatologyEmergency
Eczema Herpeticum (Kaposi Varicelliform Eruption)
Eczema Herpeticum (Kaposi Varicelliform Eruption): Suspected Eczema Herpeticum → DERMATOLOGIC EMERGENCY → Clinical Presentation → Predisposing Condition...
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Warning DERMATOLOGIC EMERGENCY
10-50% mortality if untreated
- HSV dissemination in compromised skin barrier
- Can progress to systemic viremia
- Risk of keratitis if periocular
- Requires URGENT antiviral therapy
- 1.4-3% of atopic dermatitis patients affected
03Action Clinical Presentation
Characteristic features
- Clusters of umbilicated vesicles/pustules
- Monomorphic 'punched-out' erosions
- Hemorrhagic crusting
- On areas previously affected by eczema
- Face, neck, trunk most common
- Fever, malaise, lymphadenopathy
- PAINFUL (unlike eczema flare)
04Action Predisposing Conditions
Impaired skin barrier allows HSV dissemination
- Atopic dermatitis (most common)
- Darier disease
- Pemphigus
- Ichthyosis
- Burns
- Mycosis fungoides
- Any condition disrupting skin barrier
05Action Diagnostic Workup
Confirm HSV and assess severity
- Tzanck smear: Rapid - multinucleated giant cells
- Viral culture: Gold standard (takes 2-5 days)
- HSV PCR: Rapid and specific
- Direct fluorescent antibody (DFA)
- CBC, CMP, LFTs if systemically ill
- Consider lumbar puncture if encephalitis suspected
06Warning Check for Eye Involvement
URGENT ophthalmology consult if periocular
- HSV keratitis is vision-threatening
- Dendritic ulcers on slit lamp
- Eye pain, photophobia, tearing
- Any periocular involvement → ophtho NOW
07Decision Assess Severity
Determines route of antiviral therapy
08Action Mild-Moderate: Oral Antivirals
Able to take PO, limited extent, no systemic toxicity
- Acyclovir 400-800mg PO 5x/day
- OR Valacyclovir 1g PO twice daily (better bioavailability)
- Duration: 10-14 days or until healed
- Can manage outpatient with close follow-up
- Return precautions for worsening
09Action Supportive Care
Wound care and symptom management
- Keep lesions clean and dry
- Cool compresses for comfort
- Pain management (NSAIDs, acetaminophen)
- Topical steroids: AVOID during acute HSV
- Resume topical steroids once healed to control AD
- Antibiotics only if bacterial superinfection
10Action Treat Secondary Bacterial Infection
Common complication - S. aureus most frequent
- Signs: Increased purulence, warmth, spreading erythema
- Oral antibiotics: Cephalexin or dicloxacillin
- MRSA risk: TMP-SMX or doxycycline
- IV antibiotics if cellulitis or systemic
11Action Monitoring and Follow-up
Assess response to therapy
- Clinical improvement expected within 48-72 hours
- If worsening: Consider admission, IV therapy
- Acyclovir-resistant HSV rare but possible in immunocompromised
- Complete antiviral course even if improved
- Follow-up in 1-2 weeks
12Outcome Resolution
Full recovery expected with prompt treatment
- Lesions heal in 2-4 weeks
- May leave post-inflammatory changes
- Recurrence possible (~50% have repeat episodes)
- Educate on early recognition
- Consider suppressive therapy for frequent recurrence
13Warning Complications
Without treatment, can be fatal
- HSV keratitis → corneal scarring, blindness
- Viremia, encephalitis, meningitis
- Multi-organ involvement
- Secondary bacterial sepsis
- Mortality: 10% immunocompetent, 50% immunocompromised
- Path rejoins step 11Shared downstream outcome
14Action Severe: IV Antivirals
Systemic toxicity, unable to take PO, extensive disease
- Acyclovir 5-10 mg/kg IV every 8 hours
- Admission required
- Hydration to prevent crystalline nephropathy
- Switch to oral when improving and able to take PO
- Immunocompromised: Higher doses may be needed
- Path rejoins step 09Shared downstream outcome
- Path rejoins step 07Shared downstream outcome
Guideline Source
StatPearls: Kaposi Varicelliform Eruption
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Requires clinical suspicion in atopic patients with worsening rash
- Tzanck smear provides rapid but not definitive diagnosis
- Viral culture is gold standard but takes time
- Must rule out secondary bacterial superinfection
- Recurrence possible - educate patient on early recognition
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Eczema Herpeticum (Kaposi Varicelliform Eruption)?
The Eczema Herpeticum (Kaposi Varicelliform Eruption) is a emergency clinical algorithm for Dermatology. It provides a structured decision tree to guide clinical decision-making, based on StatPearls: Kaposi Varicelliform Eruption.
What guideline is the Eczema Herpeticum (Kaposi Varicelliform Eruption) based on?
This algorithm is based on StatPearls: Kaposi Varicelliform Eruption.
What are the limitations of the Eczema Herpeticum (Kaposi Varicelliform Eruption)?
Known limitations include: Requires clinical suspicion in atopic patients with worsening rash; Tzanck smear provides rapid but not definitive diagnosis; Viral culture is gold standard but takes time; Must rule out secondary bacterial superinfection; Recurrence possible - educate patient on early recognition. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Eczema Herpeticum (Kaposi Varicelliform Eruption) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free